By comparing the clinical side effects of these two FXR ligands, vidofludimus appears to be a multi-target drug for IBD and NAFLD treatment, and the potential of DHODH inhibition in therapeutic effect and toxicity worth further exploration. This evidence concerns the gene DHODH and inflammatory bowel disease.